Advancing ADPKD Treatment with GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism
Project Number1R01DK138915-01A1
Former Number1R01DK138915-01
Contact PI/Project LeaderNOWAK, KRISTEN LYNN Other PIs
Awardee OrganizationUNIVERSITY OF COLORADO DENVER
Description
Abstract Text
Project Summary
Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder that leads to kidney
failure. The only approved treatment to decelerate kidney disease progression in patients with ADPKD is
tolvaptan, but its usage is limited due to frequent side effects affecting adherence. Thus, alternative
interventions that may slow ADPKD progression hold considerable clinical importance. In line with the general
population, body-mass index and insulin resistance have been increasing in patients with ADPKD. We have
shown that visceral adiposity associates strongly with accelerated progression of early-stage ADPKD. Our
R03-funded pilot study suggested that diet-induced weight loss may slow kidney growth (% in height-adjusted
total kidney volume [htTKV] by magnetic resonance imaging), and we are currently evaluating the efficacy of
daily caloric restriction-induced weight loss for slowing ADPKD progression in a phase IIa clinical trial.
However, the long-term adherence to lifestyle interventions is challenging, making pharmacological
interventions a compelling adjunct or alternative. Moreover, our recently completed R21-funded study
demonstrated that adults with ADPKD and preserved kidney function exhibited insulin resistance (via the gold-
standard hyperinsulinemic-euglycemic clamps) and impaired kidney oxidative metabolism (via 11C-acetate
PET), which were strongly associated with htTKV. These novel data suggest that targeting improvements in
insulin sensitivity and kidney oxidative metabolism, in addition to weight loss, may slow ADPKD progression.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) were recently FDA-approved for the treatment of
obesity and show promise in substantially reducing adiposity and improving insulin sensitivity. Additionally,
evidence indicates that GLP-1RAs may transform CKD management by reducing nephropathy events in
patients with and without diabetes, via effects extending beyond glycemic modulation, and in part via
attenuated kidney inflammation and oxidative stress. However, GLP-1RAs have not yet been evaluated as a
novel therapy for slowing ADPKD progression in patients with overweight/obesity. Thus, we propose a 24-
month, phase II, randomized, placebo-controlled, double-blind clinical trial using a GLP-1RA in 126 adults with
ADPKD and overweight or obesity to slow kidney growth (primary outcome). As a novel therapeutic in ADPKD,
GLP-1RAs could transform the treatment landscape for patients.
Specific Aim 1: Determine the effect of 24 months of GLP-1RA vs. placebo on kidney growth in adults with
ADPKD and overweight/obesity.
Specific Aim 2: Define changes in total body weight, adipose volume and function, insulin resistance, kidney
oxidative metabolism, and inflammation after 24 months of GLP-1RA vs. placebo in adults.
Specific Aim 3: Establish the safety and tolerability of GLP-1RA in adults with ADPKD and overweight/obesity.
Public Health Relevance Statement
Project Narrative
The proposed clinical trial aims to assess if a glucagon-like peptide 1 receptor agonist, a medication approved
for weight management that also improves the body's response to glucose and insulin, can slow kidney growth
in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also
evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and
urine samples will provide further insight into biological changes that may be linked to the benefits of the
intervention, while ensuring careful monitoring of safety and tolerability.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
041096314
UEI
MW8JHK6ZYEX8
Project Start Date
15-August-2024
Project End Date
31-May-2029
Budget Start Date
15-August-2024
Budget End Date
31-May-2025
Project Funding Information for 2024
Total Funding
$692,934
Direct Costs
$446,289
Indirect Costs
$246,645
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Diabetes and Digestive and Kidney Diseases
$692,934
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01DK138915-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01DK138915-01A1
Patents
No Patents information available for 1R01DK138915-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01DK138915-01A1
Clinical Studies
No Clinical Studies information available for 1R01DK138915-01A1
News and More
Related News Releases
No news release information available for 1R01DK138915-01A1
History
No Historical information available for 1R01DK138915-01A1
Similar Projects
No Similar Projects information available for 1R01DK138915-01A1